Amantadine for chronic hepatitis C: A magic bullet or yet another dead duck?

Journal of Hepatology

Volumn 35, Issue 4, 2001, Pages 527-530

  Crax, Antonio ^a   Lo Iacono, Oreste ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMANTADINE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIMANTADINE; VIRUS RNA;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EDITORIAL; HEPATITIS C; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE;

AMANTADINE; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS;

EID: 0034793732     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00184-2     Document Type: Editorial

References (37)

1. Antiviral drugs: Current state of the art
2. Rimantadine: A clinical perspective
3. Treatment of chronic hepatitis C with amantadine
4. Hepatitis C treatment with amantadine-HCl in non-responders to alpha-interferon
5. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients
6. Treatment of chronic hepatitis C with amantadine
7. Amantadine-HCl in the treatment of chronic hepatitis C in non-responders to alpha-interferon. Effect on ALT serum levels and viral load
8. Amantadine for chronic hepatitis C: Pilot study in 14 patients
9. Treatment of chronic hepatitis C with amantadine
10. Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b
11. Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin
12. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy
13. Ribavirin treatment for chronic hepatitis C
14. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C
15. Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation
16. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients
17. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders
18. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin
19. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
20. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C
21. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C
22. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs, interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy
23. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C
24. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C
25. Pegylated (40 kDa) interferon alfa-2a (Pegasys®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
26. Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: A UK multicentre study
27. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients
28. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
29. PEG interferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 Week treatment analysis of a multicenter, multinational phase III randomized controlled trial
30. Interferon alpha-2a induction therapy in combination with ribavirin and amantadine in naive patients with chronic HCV infection
31. Randomized, controlled trial with interferon-alpha combined with amantadine sulfate in primary IFN-alpha non-responsive patients with chronic hepatitis C
32. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C
33. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin
34. High daily dosing interferon alpha in monotherapy, double and triple therapy of hepatitis C non responders patients
35. Interferon induction plus ribavirin and amantadine as a novel approach for treatment non responders chronic hepatitis C patients
36. Pegylated (40 kDa) interferon alfa-2a (Pegasys) in new combination therapies: A report of a randomized, multicenter efficacy and safety study